Introduction
============

Stem cell is a term used to describe a specific type of cell with two major characteristics: the capability to differentiate into multiple cell types and the ability to maintain a self-renewing population. There are numerous classes of stem cells, varying in their source and differentiation capabilities. Embryonic stem cells are termed pluripotent owing to their ability to differentiate into cells of all three germ layers \[[@B1],[@B2]\]. Other stem cells, such as neuronal progenitor and adult stem cells, have more limited differentiation capabilities and are termed multipotent \[[@B3]-[@B6]\]. Multipotent stem cells are innately limited to differentiate only into cells from the lineages from which they were derived. Table [1](#T1){ref-type="table"} presents a list of the most relevant stem cells and their sources.

###### 

Sources, advantages and disadvantages of the main sources of stem cells

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                      Differentiation capability   Source                         Advantages                                                    Disadvantages
  --------------------------------------------------- ---------------------------- ------------------------------ ------------------------------------------------------------- --------------------------------------------------------------------------------------
  Embryonic stem cells \[[@B1],[@B2]\]                Pluripotent                  Blastocyst                     Pluripotent                                                   Ethical concerns, biomanufacturing issues

  Neuronal progenitors \[[@B3],[@B4]\]                Multipotent                  Fetal/embryonic tissue                                                                       Ethical concerns, biomanufacturing issues

  Adult central nervous system stem cells \[[@B7]\]   Multipotent                  Adult central nervous system   Autologous, no ethical concerns                               Limited differentiation potential, biomanufacturing issues, require surgical harvest

  Adult mesenchymal stem cells \[[@B5]\]              Multipotent                  Adult bone marrow              Autologous, easily obtained, no ethical concerns              Limited differentiation potential, biomanufacturing issues.

  Umbilical cord cells \[[@B8]\]                      Multipotent                  Umbilical cord                 Autologous, no ethical concerns                               Limited differentiation potential, biomanufacturing issues

  Induced pluripotent stem cells \[[@B6]\]            Multipotent/\                Skin                           Autologous, no ethical concerns, potential for pluripotency   Require addition of viral vectors for induced pluripotency, biomanufacturing issues
                                                      pluripotent                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Injury and diseases of the spinal cord have classically had a bleak prognosis. This prognosis is not solely due to the nature of the disease, which affects the spinal cord, but to the difficulty faced in developing and delivering treatments to the spinal cord, which is extremely sensitive to direct manipulation. In this review we will look at how stem cell-derived therapies are evolving into exciting therapeutics for spinal cord medicine and changing the way we think about delivering treatments to the spinal cord. As well as discussing some of the most significant current clinical trials, we will examine the route involved in realizing the bench-to-bedside translation of these therapies.

The varying array of diseases that affect the spinal cord (Table [2](#T2){ref-type="table"}) calls for a versatile and dynamic therapeutic approach. When developing any given therapeutic one must look closely at both the disease and the target tissue or tissues, carefully considering the limitations and specific barriers that must be overcome. Each disease has specific requirements and obstacles, and the treatment should be tailored to the specific disease.

###### 

Traumatic and motor neuron disease of the spinal cord, and potential for stem cell transplant

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease class   Disease/disorder                Symptoms/phenotype                                                              Mechanism                                                                            Present treatments                                          Demo-graphics                  Possibility for stem cell treatment                                                                                                              Stem cell clinical trials
  --------------- ------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Traumatic       Spinal cord injury              Varying in extent and level of injury (as classified by\                        Traumatic injury, cell loss, axonal and myelin degeneration, cytotoxic environment   Decompression and stabilization surgeries, rehabilitation   250,000 sufferers in the USA   Cell replacement, trophic support produced by transplanted cells, modified stem cells to secrete specific trophic factors, axonal regeneration   Geron Corp. ID\# NCT01217008 \[[@B9]\], Memorial Hermann Healthcare System ID\# NCT01328860 \[[@B10]\], Stem Cells Inc. ID\# NCT01321333 \[[@B11]\]
                                                  ASIA scale), loss of sensation to paralysis                                                                                                                                                                                                                                                                                                                                                                      

  Motor neuron    Amyotrophic lateral sclerosis   Neurodegeneration, muscle wastage, paralysis                                    Upper and lower motor neuron loss, glia dysfunction, both familial and sporadic      One approved drug, riluzole                                 5:100,000                      Trophic support to promote survival of motor neurons, regeneration of axons                                                                      Neuralstem Inc. ID\# NCT01348451 \[[@B12]\], BrainStorm Cell Therapeutics, Ltd ID\# NCT01051882 \[[@B13]\], TCA Cellular Therapy ID\# NCT01082653 \[[@B11],[@B14]\]

                  Spinal muscular atrophy         Childhood disease, neurodegeneration, muscle wastage, paralysis                 Inherited autosomal disease, lower motor neuron loss                                 None as of present                                          1:6,000                        Trophic support to promote survival of motor neurons, regeneration of axons                                                                      California Stem Cells Inc. \[[@B15]\]

  Inflammatory    Multiple sclerosis              Multisymptomatic presentation, including motor dysfunction and vision defects   Degeneration of myelin, due to autoimmune response                                   Steroids and anti inflammatory drug to delay progression    250,000 in the USA             Replacement of myelin producing oligodendrocytes                                                                                                 Northwestern University, Hadassah Medical Organization, Jerusalem
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASIA, American Spinal Injury Association.

Stem cells, or stem cell-derived cells, can most simply be used to replace lost cells such as oligodendrocytes, neurons, motor neurons and astrocytes. These cells may also provide an additional therapeutic effect by secreting factors that are neuroprotective or that promote neuroregeneration, such as cytokines and growth factors \[[@B16]\]. The modification of stem cells via gene therapy to produce or reduce specific factors is an additional level of specificity, which allows the therapeutic to target specific aspects of the disease under investigation \[[@B17]\].

Before discussing the use of stem cells and stem cell-derived cells, it is important to pause for a moment to consider the ethical issues associated with their use.

There is an ongoing debate regarding the ethics of using cells that are derived from human fetal and embryonic origins. The destruction of these fetuses and embryos for research is of great ethical concern and debate. We shall not enter into this debate in the present review; interested readers may wish to refer to the National Institutes of Health webpage on this issue \[[@B18]\].

Delivery methods
================

Several promising methods are employed for transplanting stem cells into the spinal cord. Intravascular infusion, intrathecal infusion and direct intraparenchymal injection have all been utilized in human clinical trials (see Table [3](#T3){ref-type="table"}). While these methods have been used in the clinic, the most effective method has yet to be determined. This uncertainty remains a critical debate with major implications for the future success of stem cell therapy in the spinal cord.

###### 

Current clinical trials transplanting stem cells into the spinal cord

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year   Location/sponsor                                                               Cells                                                                                    Indication   Delivery                                                                                                                                                       Inclusion criteria                                                                                                  Status                                                References
  ------ ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------
  2009   Palo Alto, CA; Atlanta, GA; Chicago, IL; Philadelphia, PA, USA (Geron Corp.)   Allogenic human ESC-derived oligodendrocytes (GRNOPC1^®^)                                SCI          Direct single injection to the spinal cord lesion using a table-mounted syringe positioning\                                                                   Adult subacute complete thoracic SCI (ASIA grade A)                                                                 FDA phase 1. Terminated                               ID\# NCT01217008 \[[@B9],[@B11]\]
                                                                                                                                                                                              device (2 million cells)                                                                                                                                                                                                                                                                                                                 

  2010   Atlanta, GA, USA (Neuralstem Inc.)                                             Allogenic human fetal spinal cord-derived spinal stem cells (NSI-566RSC)                 ALS          Direct multiple injections to the ventral horn of the lumbar or cervical enlargement using a spine-mounted microinjection platform (0.5 to 1 million cells)    Adult probable or definite ALS defined according to El Escorial criteria                                            FDA phase 1. Recruiting                               ID\# NCT01348451 \[[@B11],[@B12]\]

  2011   Irvine, CA, USA (California Stem Cell, Inc.)                                   Allogenic human ESC-derived motor neuron progenitor cells (MotorGraft™)                  SMA          Direct multiple injections to the ventral horn of the thoracic spinal cord                                                                                     Infant (age 2 to 6 months) SMA type 1                                                                               FDA clinical hold. Reviewing IND                      \[[@B15]\]

  2001   Italy                                                                          Autologous human bone marrow-derived mesenchymal stem cells                              ALS          Direct multiple injections to the central gray matter of the lumbar enlargement using a table-mounted injector (7 to 152 million cells)                        Adult definite ALS defined according to El Escorial criteria                                                        Phase 1. Completed                                    Mazzini and colleagues \[[@B19]-[@B21]\]

  2011   Zurich, Switzerland (Stem Cells Inc.)                                          Allogenic fetal brain-derived human central nervous system stem cells (HuCNS-SC^®^)      SCI          Direct multiple injections to the inferior and superior border of spinal cord lesion (20 million cells)                                                        Adult thoracic chronic SCI (ASIA grade A, B, or C)                                                                  Swiss medic phase 1/2. Recruiting                     ID\# NCT01321333 \[[@B11],[@B22]\]

  2011   Jerusalem, Israel (BrainStorm Cell Therapeutics, Ltd)                          Autologous human mesenchymal bone marrow stromal cells secreting neutrotrophic factors   ALS          Early stage: multiple intramuscular injections to triceps and biceps muscles (24 million cells). Late stage: single intrathecal injection (60 million cells)   ALS disease duration \<2 years; *and*ALS-FRS-R scale \>30 (early stage) *or*ALS-FRS-R scale 15 to 30 (late stage)   Israel Ministry of Health phase 1/2. Recruiting       ID\# NCT01051882 \[[@B11],[@B13]\]

  2011   Houston, TX, USA (Memorial Hermann Healthcare System)                          Autologous human bone marrow-derived progenitor cells                                    SCI          Single intravenous infusion                                                                                                                                    Children age 1 to 15 years with chronic SCI                                                                         FDA phase 1. Recruiting                               ID\# NCT01328860 \[[@B10],[@B11]\]

  2010   Covington, LA, USA (TCA Cellular Therapy, LLC)                                 Autologous human bone marrow-derived mesenchymal stem cells                              ALS          Single intrathecal infusion                                                                                                                                    Moderate to severe ALS with El Escorial criteria                                                                    FDA phase 1. Ongoing                                  ID\# NCT01082653 \[[@B11],[@B14]\]

  2010   Covington, LA, USA (TCA Cellular Therapy, LLC)                                 Autologous human bone marrow-derived mesenchymal stem cells                              SCI          Single intrathecal infusion                                                                                                                                    Subacute complete SCI below C-5 (ASIA grade A)                                                                      FDA phase 1. Ongoing                                  ID\# NCT01162915 \[[@B11],[@B14]\]

  2010   Rochester, MN, USA (Mayo Clinic)                                               Autologous human adipose tissue-derived mesenchymal stem cells                           ALS          Single intrathecal infusion (1 million cells)                                                                                                                  Adult with chronic onset of a progressive motor weakness                                                            FDA phase 1. Ongoing                                  ID\# NCT01142856 \[[@B11]\]

  2000   Israel and Belgium (Proneuron Biotech)                                         Autologous human macrophages                                                             SCI          Direct multiple hand-held injections at the caudal border of the spinal cord lesion (4 million cells)                                                          Adult acute\                                                                                                        Phase 1.\                                             ID\# NCT00073853 \[[@B11]\]
                                                                                                                                                                                                                                                                                                                                                             complete SCI\                                                                                                       Suspended                                             
                                                                                                                                                                                                                                                                                                                                                             between C5 and\                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                             T11 (ASIA grade A)                                                                                                                                                        

  2006   Jerusalem, Israel (Hadassah Medical Organization)                              Autologous human bone marrow-derived mesenchymal stem cells                              MS           Intrathecal infusion of 60 million cells and intravenous infusion of 20 million cells                                                                          Definite MS                                                                                                         Israel Ministry of Health phase 1/2. Status unknown   ID\# NCT00781872 \[[@B11]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALS, amyotrophic lateral sclerosis; ALS-FRS-R, Amyotrophic lateral sclerosis functional rating scale-revised; ASIA, American Spinal Injury Association; ESC, embryonic stem cell; FDA, US Food and Drug Administration; IND, investigational new drug; MS, multiple sclerosis; SCI, spinal cord injury; SMA, spinal muscular atrophy.

Systemic delivery methods, such as intravascular and intrathecal infusion, rely on the stem cells\' ability to migrate to local areas of pathology. While this migration capability has been well described in small animal models, convincing evidence in large animal models is still lacking \[[@B23]-[@B25]\]. Regardless, systemic approaches have been used in many stem cell clinical trials in the spinal cord but with limited success. In a trial for chronic spinal cord injury (SCI), magnetically labeled autologous bone marrow CD34^+^cells delivered by intrathecal infusion and visualized by magnetic resonance imaging (MRI) were shown to migrate to the injured site \[[@B26]\]. Migration has been noted in other trials in the spinal cord using systemic approaches \[[@B27]\].

Direct intraparenchymal injection delivers stem cells directly to the area of pathology and does not require systemic migration of cells. Paul and colleagues compared different methods of mesenchymal stem cell (MSC) transplantation in a rat model of SCI \[[@B28]\]. Twenty-one days after a single dose, 6.1% of cells engrafted with direct intraparenchymal injection compared with 3.4% and 1.6% with intravenous infusion and intrathecal infusion, respectively. This study demonstrated that direct injection is the preferred method of delivery even with only 6.1% of cells detectable 21 days post transplantation in a rat spinal cord. Furthermore, direct spinal cord injection allows for accurate and reliable delivery that can easily be scaled up to humans, but carries the additional risk of manipulation of spinal cord pathology.

Various approaches for direct intraparenchymal injection have been developed. All direct injection approaches require a multilevel laminectomy and opening of the dura mater to expose the spinal cord. In small animal studies, intraparenchymal injections are frequently and successfully performed without stabilization using a free-hand method \[[@B29],[@B30]\]. This presents several problems for translation to humans. First, it does not allow reliable targeting in the spinal cord. Second, the unsteady needle can move and shear white matter tracts. Finally, the uncontrolled rate of injection promotes reflux of the therapeutic agent up the cannula track and increases the risk for spinal cord mass effect by elevated intraparenchymal pressure. In spite of these inherent risks, free-hand intraparenchymal injections of stem cells have been performed in several clinical trials for SCI and amyotrophic lateral sclerosis (ALS) with limited success \[[@B31]-[@B34]\]. Moreover, because no device is used in this approach, there are no additional regulatory hurdles associated with using a novel device.

Injection systems mounted on the operating room table provide several advantages over the free-hand approach \[[@B35],[@B36]\]. When used with microinjection pumps and micromanipulators, table-mounted systems allowed better control over the injection rate and pressure and more accurate landmark-based targeting. The table-mounted system also provides a degree of stability to the injection cannula. However, this system does not account for movement of the patient or spinal cord with respect to the injection cannula. Ventilation-associated motion of the patient, cardiovascular pulsation of the spinal cord and movement of the patient or table-mounted injection system may lead to injury of an already weakened spinal cord.

To address the concerns of potential procedural morbidity and suboptimal accuracy, our group developed an injection system that mounts to the patient\'s spine for optimal stability \[[@B37]-[@B40]\]. The injection platform can be immobilized relative to the spine with percutaneous mounts attached to vertebral pedicles flanking the injection site. The spine mounts allow the injection system to move with the patient during ventilation and in the event of inadvertent patient movement. The stabilized platform also allows for accurate landmark-based targeting with the adjustable microinjector attached to the platform. The platform allows for rostrocaudal displacement and angular manipulations in the coronal, sagittal and axial planes of the microinjector to accommodate multilevel injections. This injection system utilizes an outer rigid cannula for accurate targeting and an inner flexible or floating cannula for cell delivery. The flexibility provided by the floating cannula compensates for the natural pulsation of the spinal cord with ventilation and heartbeat These innovations reduced the procedural risks associated with direct intraparenchymal injection and improved targeting capability \[[@B40]\]. The safety and accurate targeting using this system has been extensively assessed by preclinical work \[[@B38],[@B40],[@B41]\]. Initial use of this delivery system in a clinical setting has shown encouraging results \[[@B42],[@B43]\]. While these innovations allow for safer and more accurate delivery, many improvements must be made to further optimize the delivery of stem cells to the human spinal cord, such as incorporating image-guided techniques.

Stem cells in clinical trials for treatment of the spinal cord and their journey from bench to bedside
======================================================================================================

To facilitate the translation of stem cells from bench to bedside and to satisfy all regulatory bodies, extensive preclinical work in animal models must be undertaken and must provide sufficient evidence that the proposed treatment is both safe and effective. The translation process from basic research through investigational new drug to human clinical trials is long and complex. For an in-depth review on the regulatory progress of translation of stem cell treatments, please see the comprehensive review by Aboody and colleagues \[[@B44]\].

Before we look at the translations of stem cells to the clinic we must take note of the caveats that are linked to stem cells, as with all developing therapeutics. Extensive preclinical work must establish that there is no risk of tumor formation, which is a major safety concern when dealing with stem cells. The immune response and rejection of nonautologous cells is also a considerable concern for stem cell researchers and clinicians. This rejection necessitates that many patients who received stem cell transplants are required to take immunosuppressive drugs, which in turn have their own adverse effects and complications. It is also important to note that the generation of clinical-grade stem cells is subjected to its own unique obstacles that have to be overcome, such as kartotype problems and removal of substances utilized during biomanufacturing.

Geron Corp. (Menlo Park, CA, USA) was the first company to bring human embryonic stem cell-derived cells through US Food and Drug Administration (FDA) approval for human phase 1 clinical trials. Owing to this important first, the Geron Corp. trial gained attention in both the scientific world but also in the general media. Geron Corp.\'s combination of stem cell type and disease demonstrates the specific tailoring required for stem cell translation. They chose to look at stem cell transplantation for SCI. Following SCI, a glial scar and cyst are formed, many surviving axons are subjected to myelin loss, and cytotoxic and inhibitory factors are produced by the glial scar \[[@B45]\]. Human embryonic-derived oligodendrocyte precursor cells injected into the injured rodent spinal cord have been shown to migrate to the lesion site, to provide trophic support to surviving axons, and also to differentiate into mature oligodendrocytes that are capable of remyelination of the surviving axons. The combination of cell replacement and trophic support brought about significant locomotor improvement in the rodent model and long-term remyelination of the surviving and regenerated axons. Geron Corp. and their collaborators embarked on an extensive preclinical safety study in a rodent model of SCI. This study examined teratoma formation, toxicity, cyst formation, allodynia and allogenic immune response. Despite the absence of a large animal study, Geron Corp. was granted FDA approval for the delivery of human embryonic stem cell-derived oligodendrocyte precursor cells into the lesion site of subacute thoracic SCI. It is important to note not only that the scientific precedence set by this trial but also the approval of the trial using embryonic stem cells went a long way in dealing with the ethical issues surrounding the use of these and other embryonic stem cells. Specific details of this trail can be found online \[[@B9]\].

Neuralstem Inc. (Atlanta, GA, USA) and their collaborators chose to pursue the ALS agenda as a disease state for which stem cells can offer a potentially powerful therapeutic. ALS is a complex disease involving motor neuron loss, muscle innervation loss and glia dysfunction.

Simple cell replacement is not sufficient to result in reinnervation of affected muscles. Transplanted cells must provide both cell replacement and trophic support \[[@B46],[@B47]\]. The trophic support may be from the stem cells\' own endogenous growth factor profile, or the cells may be modified to produce specific growth factors via *ex vivo*gene therapy \[[@B48]-[@B50]\]. Again this concept of both cell replacement and trophic support demonstrates that stem cells\' positive attributes are not mutually exclusive in a therapeutic setting. Owing to the discovery of the SOD-1 mutation in familial ALS, a rodent model of ALS was developed - giving us a reliable model in which to observe the development of the disease and a platform from which to examine the potential of stem cell transplantation in this disease state \[[@B51]-[@B53]\]. In-depth research has been carried out to prove the efficacy of stem cell transplantation in the SOD-1 rodent models. Human spinal stem cells have been shown to reduce loss of motor neuron and prolong SOD-1 rat survival \[[@B17],[@B47],[@B54]\]. Following these promising results in rodent models, Neuralstem Inc. and their collaborators embarked on large-animal safety studies. Pigs were chosen as the best model due to the similarity to the human spinal cord. The pig experiments allowed the cord\'s tolerance to injection doses and number of injections to be determined. In combination with this critical safety study, rodent efficacy data and the development of a novel injection platform to reduce surgical complexity, Neuralstem Inc. and their collaborators were the first to receive approval for the first translational trial of stem cells for the treatment of ALS. This trial is presently in phase 1 to evaluate the safety and feasibility of direct injection of stem cells into the spinal cord. A positive outcome of this phase 1 safety trial will pave the way for the continued translation of stem cells \[[@B42],[@B43]\].

California Stem Cell, Inc. (Irvine, CA, USA) and the University of California, Irvine worked together on developing embryonic stem cell-derived motor neuron progenitors as a potential therapeutic approach for spinal muscular atrophy. An autosomal recessive neuromuscular disease, spinal muscular atrophy is the leading genetic cause of mortality in children. Spinal muscular atrophy is characterized by muscle paralysis and atrophy, associated with loss of spinal cord motor neurons \[[@B55],[@B56]\]. California Stem Cell, Inc.\'s motor neuron progenitors have been shown to improve neuronal survival in three separate models of spinal muscular atrophy \[[@B57]\] and also have shown functional recovery in models of SCI \[[@B58]\]. California Stem Cell, Inc. branded these cells Motorgraft and received investigational new drug status in 2010. Following review the FDA placed this potential trial on clinical hold. California Stem Cell, Inc. is currently working to address the FDA comments and recommendations necessary for approval.

In Europe a team of Italian scientists and physicians have been progressing the adult stem cell agenda. MSCs have been showed to have anti-inflammatory effects, which have been observed to reduce the inflammatory and reactive state of microglia and astrocytes, promoting a protective microenvironment \[[@B59]\]. Human MSCs have been observed to improve motor function and reduce inflammation in a mouse model of ALS \[[@B60]\]. MSC harvested from ALS patients has been shown to present the same differentiation potential as those from normal donors and they have no other observable chromosomal or cellular abnormalities \[[@B61]\]. These findings suggest that the autologous cells can be used, eliminating the risk of host rejection and the need for immunosuppression. This work has proceeded to clinical trial. The first phase I safety data from this trial showed no adverse effect \[[@B19]\]. The long-term safety results of this trial (\>8 years) showed no adverse effects \[[@B20]\]. No beneficial effects were observed. A more comprehensive trial is called for to assess the potential of these adult stem cells.

Optimizing delivery
===================

Future methods of transplanting stem cells into the spinal cord must aim to both improve targeting capabilities and reduce procedural morbidity. Advanced imaging and image-guided techniques offer a means to accomplish both of these aims. MRI can allow for direct targeting of spinal cord anatomy and pathology with its unparalleled spatial resolution in the central nervous system.

Current clinical trials directly injecting stem cells utilize MRI for preoperative planning and naked-eye visual observation of spinal cord surface anatomy for calculating the final injection site. Although the current method is accurate, direct visualization of the injection cannula within the spinal cord using MRI would offer greater targeting accuracy and confirm the location of the injected cells. MRI-guided approaches are well established in the brain for implantation of deep brain stimulation electrodes \[[@B62],[@B63]\] and various other procedures. With the increasing availability of intraoperative MRI suites, the prospect of injecting stem cells directly into the spinal cord during surgery with the guidance of realtime MRI is becoming a reality. However, modifications must be made to the current generation of injection devices to make them MRI compatible.

Further improvements may create intraoperative MRI injection devices capable of direct delivery to the spinal cord parenchyma percutaneously, eliminating the need for open surgery. Before this is possible, extensive preclinical validation must be done in large animal models to assess targeting ability and morbidity associated with the new procedure. Directly injecting cells percutaneously creates many new concerns: cerebrospinal fluid leak associated with multiple punctures of the dura mater; uncontrolled hemorrhage from damaged spinal cord blood vessels; inaccurate targeting due to displacement of the spinal cord from cannula insertion; and a limited range of injection sites due to obstruction from the vertebral column.

Cell tracking
=============

Another critical issue faced in most stem cell trials is the inability to monitor the cell grafts post transplantation. This inability has made it difficult to understand the fate of the graft *in vivo*, specifically in terms of cell graft location, survival and migration. Furthermore, even identifying the cell graft on postmortem tissue histology can prove challenging due to the low number of cells and limitations in histological techniques. These critical issues highlight the need for a cell label that allows for *in vivo*visualization and/or postmortem detection.

Cells may be visualized *in vivo*when labeled with a biomarker or contrast agent prior to transplantation. Many different approaches have been used to label stem cells, such as superparamagnetic iron oxide (SPIO) particles for MRI visualization, radionuclides for positron emission tomography and/or single-photon emission computed tomography visualization and reporter genes for a wide variety of imaging modalities. Methods for labeling stem cells have been well described and have been utilized in a wide variety of clinical trials \[[@B64],[@B65]\].

The ability to track SPIO particle-labeled stem cells transplanted into the central nervous system has been validated in numerous small animal studies and demonstrated in several clinical trials \[[@B26],[@B27],[@B66]-[@B69]\]. These pioneering trials confirm both the ability to visualize labeled stem cells *in vivo*and the safety of these labeling approaches. Initially, these labeling methods proved most valuable in determining an initial graft location \[[@B69],[@B70]\]. However, the follow-up imaging on these few patients was not long term and postmortem staining for localization of SPIO particles was not performed. Rodent studies have shown that SPIO-labeled cells can be visualized with MRI and identified in histological tissue samples up to a year after transplantation \[[@B66]\]. Caution should be exercised when using this approach to track cells long term, however, as the contrast produced by the SPIO particles is dependent on a high density of cells and the amount of contrast from the SPIO particles is finite. As the cells divide, the contrast produced is reduced by a factor of two for the individual cell. Additionally, the particles can be visualized after being ingested by phagocytosing cells, leading to a false positive signal on MRI \[[@B71]\]. More investigation, specifically long-term translational work, must be carried out to determine the utility of SPIO particles as a long-term cell label.

The majority of clinical trials transplanting stem cells into the spinal cord do not incorporate a method for tracking cells *in vivo*. This limitation makes it difficult to confirm that the stem cells have been delivered successfully to the target and even more difficult to track their progress over time. Furthermore, without an effective label, postmortem histological identification is difficult when using conventional methods of identifying the different origins of chimeric tissue. Methodologies for labeling stem cells to track them *in vivo*and identify them postmortem have great potential. Overcoming these technological hurdles to develop a successful label is essential for progressing the field of stem cell transplantation.

Conclusion
==========

Basic stem cell research and stem cell translational agendas present an exciting and promising future for spinal cord regeneration. Progress and advancements made within the field of spinal cord medicine will have positive ramifications in the larger stem cell field and numerous other disease states outside the central nervous system. Pioneering work - like that of Geron Corp. and Neuralstem Inc. - not only has advanced the stem cell agenda on the scientific front, but also has made great strides toward overcoming the ethical taboo associated with embryonic stem cells, and has aided other researchers in progressing to clinical trials.

Huge strides have already been made in the translation of stem cells to the clinic. Promising results have been obtained in the preclinical setting and in establishing basic safety data in clinical trials - although it is important to remember that the translation of stem cells to the clinic is still in its infancy, and there are still important hurdles to be overcome and caveats that must not be overlooked. Future work needs to focus on optimizing the delivery and *in vivo*tracking of the fate of stem cells following transplantations. Great care also needs to be taken with the development of each new source of stem cells, to ensure karotype stability and in screening for potential tumor formation and other adverse events.

With these caveats and future advancements taken into account, this is an exciting time for stem cell medicine and spinal cord medicine. We are only beginning to scrape the surface of the huge potential that stem cells tailored to spinal cord application can offer. However, as is often the case in initial trials to test novel technologies, there will probably be clinical failures before we see successes.
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Note
====

This article is part of a thematic series on Clinical applications of stem cells edited by Mahendra Rao. Other articles in the series can be found online at <http://stemcellres.com/series/clinical>
